I-MAB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 USD | -1.13% |
|
-3.31% | -7.89% |
| Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
| Apr. 15 | I-Mab Announces Chief Medical Officer Changes | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,324 | 3,647 | 347.4 | 142.8 | 142.8 | - |
| Enterprise Value (EV) 1 | 3,324 | 3,093 | -149 | 157.7 | 142.8 | 142.8 |
| P/E ratio | 44.5 x | -22.6 x | -0.99 x | -0.82 x | -1.22 x | -1.61 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 14.1 x | 264 x | -10.8 x | 40.5 x | 190 x | 190 x |
| EV / Revenue | 14.1 x | 264 x | -10.8 x | 40.5 x | 190 x | 190 x |
| EV / EBITDA | 126,766,580 x | -11,718,912 x | -1,296,513 x | - | - | - |
| EV / FCF | 50.6 x | -24 x | -2.09 x | -1.07 x | -1.88 x | -1.77 x |
| FCF Yield | 1.98% | -4.16% | -47.8% | -93.8% | -53.3% | -56.6% |
| Price to Book | 8.95 x | 11.5 x | 1.83 x | - | - | - |
| Nbr of stocks (in thousands) | 70,496 | 76,963 | 83,099 | 80,702 | 80,702 | - |
| Reference price 2 | 47.15 | 47.39 | 4.180 | 1.770 | 1.770 | 1.770 |
| Announcement Date | 3/29/21 | 3/29/22 | 3/31/23 | 3/14/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.823 | 4.226 | 235.8 | 13.81 | -32.12 | 3.893 | 0.75 | 0.75 |
| EBITDA | - | -205.6 | 26.22 | -311.2 | -267.9 | - | - | - |
| EBIT 1 | - | -206.4 | 23.78 | -325.1 | -271.7 | -174.1 | -177.4 | -160.3 |
| Operating Margin | - | -4,883.22% | 10.08% | -2,353.06% | 845.79% | -4,471.87% | -23,646.86% | -21,374.43% |
| Earnings before Tax (EBT) 1 | - | -204.5 | 73.86 | -366.4 | -349.6 | -206.4 | -157.7 | -146.4 |
| Net income 1 | - | -209.2 | 71.99 | -365.9 | -349.7 | -206.4 | -157.7 | -146.4 |
| Net margin | - | -4,950% | 30.53% | -2,648.7% | 1,088.53% | -5,302.83% | -21,026.27% | -19,515.09% |
| EPS 2 | -8.970 | -65.39 | 1.060 | -2.095 | -4.240 | -2.330 | -1.451 | -1.102 |
| Free Cash Flow 1 | - | -124.3 | 65.69 | -151.8 | -166.2 | -134 | -76.1 | -80.8 |
| FCF margin | - | -2,942.09% | 27.85% | -1,098.7% | 517.38% | -4,934.69% | -10,146.67% | -10,773.33% |
| FCF Conversion (EBITDA) | - | - | 250.52% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | 91.25% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 7/29/19 | 3/31/20 | 3/29/21 | 3/29/22 | 3/31/23 | 3/14/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 Q4 | 2020 S2 | 2021 Q1 | 2021 Q2 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 Q1 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 235.8 | 235.8 | 1.233 | 1.233 | 2.753 | 4.874 | 5.316 | 11.02 | 3.597 | 3.597 | 7.742 | -39.87 | - | - | 3 | - | - | 0.75 | 0.75 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -86.86 | 178.1 | 117.6 | -66.37 | -66.37 | -159 | -67.63 | -73.77 | -163.9 | -56.91 | -56.91 | -122.5 | -149.2 | -53.86 | -53.14 | -95.61 | -84.7 | -43.78 | -85.26 | -84.68 |
| Operating Margin | - | 75.51% | 49.86% | -5,381.45% | -5,381.45% | -5,776.17% | -1,387.67% | -1,387.67% | -1,486.94% | -1,582.07% | -1,582.07% | -1,582.16% | 374.28% | - | - | -3,187.03% | - | - | -11,368.4% | -11,291.07% |
| Earnings before Tax (EBT) 1 | -82.5 | 161.1 | 163 | -74.89 | -74.89 | -167.2 | -87.06 | -94.96 | -197 | -72.62 | -72.62 | -156.3 | -112.3 | -53.86 | -53.14 | -112.9 | -97.25 | -43.78 | -78.54 | -65.63 |
| Net income 1 | -82.5 | 159.2 | 161.1 | -74.67 | -74.67 | -166.7 | -87.06 | -94.96 | -197 | -72.62 | -72.62 | -156.3 | -112.3 | -53.86 | -53.14 | -112.9 | -97.25 | -43.78 | -78.54 | -65.63 |
| Net margin | - | 67.52% | 68.31% | -6,054.45% | -6,054.45% | -6,056.12% | -1,786.31% | -1,786.31% | -1,786.54% | -2,018.63% | -2,018.63% | -2,018.75% | -449.24% | - | - | -3,761.9% | - | - | -10,472.18% | -8,750.1% |
| EPS 2 | -1.558 | 1.158 | 2.618 | -1.018 | -1.018 | -2.280 | -1.110 | -1.211 | -1.094 | -0.8837 | -0.8837 | -1.900 | -2.340 | -0.2800 | -0.2740 | -1.310 | -0.8465 | -0.2200 | -0.5455 | -0.4820 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/31/20 | 3/29/21 | 3/29/21 | 11/10/22 | 8/31/21 | 8/31/21 | 11/10/22 | 3/29/22 | 3/29/22 | 11/10/22 | 8/30/22 | 8/30/22 | 3/31/23 | - | - | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | 554 | 496 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -124 | 65.7 | -152 | -166 | -134 | -76.1 | -80.8 |
| ROE (net income / shareholders' equity) | - | -95.8% | 26.2% | -45.6% | -9.24% | - | - | - |
| ROA (Net income/ Total Assets) | - | -70.6% | 11.7% | -39% | -7.23% | - | - | - |
| Assets 1 | - | 296.3 | 616.9 | 938.7 | 4,837 | - | - | - |
| Book Value Per Share | - | -82.90 | 5.270 | 4.130 | 2.280 | - | - | - |
| Cash Flow per Share | - | -38.80 | 0.4300 | -0.8400 | -0.8400 | - | - | - |
| Capex 1 | - | 1.73 | 1.24 | 4.53 | 6.63 | 6.6 | - | - |
| Capex / Sales | - | 40.93% | 0.52% | 32.79% | -20.64% | 243.05% | - | - |
| Announcement Date | 7/29/19 | 3/31/20 | 3/29/21 | 3/29/22 | 3/31/23 | 3/14/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.77
USD
Average target price
7.25
USD
Spread / Average Target
+309.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.89% | 143M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- IMAB Stock
- Financials I-Mab